Asciminib Pediatric formulation group clinical trials

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

This study is looking at a medicine called asciminib for children and teenagers (1 to 17 years old) with a type of blood cancer called CML. Researchers want to find the right dose for different ages and check how safe the medicine is, especially for those who have tried other similar treatments.